Xcout IntelResverlogix
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Subscribe to see Resverlogix’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Resverlogix at a glance
Resverlogix is a biotech company headquartered in Calgary, Canada. It is publicly listed (RVX) with a market capitalisation of $23.6M. Xcout tracks 2 named people at Resverlogix, including Donald McCaffrey (Co-Founder).
Resverlogix leadership
- Donald McCaffreyCo-Founder
- Norman WongCo-Founder
Resverlogix competitors
A few of Resverlogix's closest competitors — see the full list of competitors and alternatives →
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Evrys Bio, LLC is a biotechnology company developing first-in-class therapeutics designed to treat a broad spectrum of viral infections and prevent drug resistance. The company utilizes allosteric, small molecule SIRT2 modulators that target host cells to suppress viral infections and shift metabolic reprogramming.
Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.
Thryv Therapeutics Inc., formerly known as LQT Therapeutics Inc., is a privately owned clinical-stage biotechnology company based in Montreal, Quebec, Canada. The company pioneers targeted therapeutic treatments addressing serious medical conditions. Operating out of its downtown Montreal headquarters, the firm manages dedicated research and development programs.
Rejuveron Life Sciences AG is a biotechnology company headquartered in Schlieren, Switzerland, focused on developing innovative therapeutics and therapies for aging-related diseases and longevity.
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Get Resverlogix's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Resverlogix in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access